Gencurix, Inc.

Gencurix, a company specializing in cancer diagnostics, has been working to expand its presence in global markets by participating in the American Association for Molecular Pathology (AMP 2024) annual meeting, showcasing its digital PCR-based cancer diagnostic technologies and companion diagnostic products. https://lnkd.in/ga3YYmJi

Missed the IDT x Gencurix webinar?  Don't worry, you can watch it anytime, anywhere using the link below. Just click on it now. https://lnkd.in/gQJCYVym #Gencurix #Droplex #digitalPCR #EGFR #NSCLC #POLE #EndometrialCancer #ESR1 #BreastCancer

Gencurix, a company specializing in cancer molecular diagnostics, announced on the 7th that it has signed a partnership agreement with Roche Diagnostics Korea, a subsidiary of global IVD leader Roche Diagnostics, to develop and commercialize cancer diagnostic kits using digital polymerase chain reaction (digital PCR) technology. https://lnkd.in/g3sij9ZS

You heard a lot about PCR Testing during the pandemic. Do you know what Digital PCR is? I am delighted to share an exciting news released today that Roche Diagnostics Korea and Gencurix form a strategic partnership in the exploration of the real-world applications of Digital PCR. Digital PCR is a far more powerful technique than the conventional PCR. Given its unique precision and sensitivity capabilities, Digital PCR is able to detect minimal DNA or RNA molecules, making it a powerful tool for cancer research and personalized cancer treatment. The passion and efforts of a group of highly committed professionals at Gencurix, Inc. and Roche Diagnostics Korea (한국로슈진단) made this partnership happen. Congratulations! KunSub Ji | Youngho Lee | Donghwa Shin | Heewon Seo | JinJoo Jeon | JaeYoung Lee | Geunhee Hahn | Hongsang Choi | Doohyun Nam #RocheDiagnosticsKorea #Gencurix #Roche #PCR

Gencurix and IDT are teaming up to host a webinar for researchers interested in digital PCR. 😀 The webinar will include an introduction to the latest cancer research using digital PCR, as well as Gencurix's Droplex EGFR, POLE and ESR1 mutation tests. We look forward to your participation. 😊

🌈 Great News! 😀 Results from a study using Gencurix's companion diagnostic in vitro diagnostic, the Droplex EGFR Mutation Test v2, have been published.  The study reported the results of an updated analysis of the overall survival (OS) and safety of lazertinib 240 mg/day in patients with advanced EGFR T790M-positive NSCLC who had been previously treated with an EGFR-TKI in the LASER201 trial, as well as the results of a circulating tumour DNA (ctDNA) analysis performed to identify potential associations between detected EGFR mutations and patient outcomes. In this study, ctDNA clearance was confirmed by Gencurix's ddPCR-based Droplex EGFR Mutation Test v2, which showed that the 'cleared' group overall had a better prognostic trend in key anti-tumor efficacy endpoints including Objective Response Rate (ORR), Disease Control Rate (DCR), Progression-Free Survival (PFS) and Overall Survival (OS) compared to the 'not cleared' group at baseline, cycle 3 and cycle 5. In particular, significant prognostic superiority was observed for PFS, ORR and DCR at cycle 3. The study's findings highlight the exciting potential of plasma EGFR mutation clearance as a predictor of clinical outcomes in EGFR-mutated NSCLC patients. 👏 Huge congratulations to everyone involved in this impactful research! 🌟 Droplex EGFR Mutation Test v2 : https://lnkd.in/ge7AXdHW #Gencurix #Droplex #NSCLC #Lazertinib #EGFR #ctDNA #CompanionDiagnostics #CancerResearch #PrecisionMedicine #ddPCR

👏 At the 2024 European Society for Medical Oncology (ESMO), ABION announced promising results regarding its drug, 'Bavamekip' (ABN401), which targets patients with MET overexpression using circulating tumor cells (CTCs) as biomarkers. 👉 Title: Concordances assessment between MET-positive circulating tumor cells and disease progression in patients with EGFR-mutated NSCLC CTCs were isolated using GenoCTC® (Genobio Corp, Seoul, Republic of Korea). Cells were stained using the GenoCTC profiling kit (Genobio Corp), then visualized and analyzed using the BioView DeNovo system (BioView Inc., Israel), an automated imaging and analysis platform. Bavamekip is the only drug, provided directly by Janssen (which holds the global rights to Yuhan's 'Lecraza'), to enter combination therapy clinical trials. The study focused on patients with EGFR-mutant non-small cell lung cancer (NSCLC). The detection of MET mutations, which are associated with resistance to EGFR-targeted therapies like Tagrisso and Lecraza, was achieved through CTC monitoring. This approach helps identify patients early who might benefit from Bavamekip and Lecraza combination therapy. ABION's study, led by researchers from Samsung Medical Center, revealed that rising CTC levels are indicative of poor prognosis and emerging drug resistance, particularly to EGFR inhibitors. The use of CTCs allowed for early detection of MET-positive patients, improving the chances of addressing resistance promptly. Additionally, ABION used its proprietary antibodies to capture MET-positive cells, marking the first study to isolate MET-overexpressing cells in lung cancer using protein antibodies. CTCs are considered a valuable tool for selecting patients for combination therapies and could also be used for companion diagnostics if correlations between CTC results and drug efficacy are confirmed.   #Gencruix #GenoBio #GenoCTC #CTC #Abion #ESMO2024 #NSCLC

👏 Gencurix introduced new technologies at ESMO Congress 2024. Title: Development and Validation of a Novel Digital PCR Assay Targeting Circulating Tumor DNA Methylation Biomarkers for Hepatocellular Carcinoma Screening.   Gencurix's digital PCR-based test for early liver cancer detection, 'HEPA eDX,' gained significant attention at the 2024 European Society for Medical Oncology (ESMO) event. The test, which previously detected two biomarkers, now detects four, significantly improving diagnostic accuracy by multiplex digital PCR (QX600). 👀   HEPA eDX identifies methylated biomarkers in circulating tumor DNA (ctDNA) from blood samples, using data from over 10,000 samples to select optimal liver cancer biomarkers. A study, in collaboration with Inje University, confirmed the test’s effectiveness in diagnosing liver cancer, showing higher methylation levels in liver cancer than other cancers.   In tests on 160 participants, HEPA eDX achieved 77% sensitivity and 92% specificity. When combined with the serum AFP test, both measures increased to 92%. The updated platform can now monitor liver cell damage and the progression of liver disease, providing early detection of liver cancer risk. It can also be used for post-liver transplant monitoring to detect recurrence or rejection. 👍   Gencurix is preparing HEPA eDX for commercialization through clinical trials. https://lnkd.in/g8_eTtRX #Gencurix #ESMO2024 #HEPAeDX #QX600 #digitalPCR #dPCR

Gencurix, a leading cancer molecular diagnostics company, presented research findings on its Droplex NSCLC Panel Test in a eposter at the WCLC 2024 conference, held in San Diego, USA, from September 7-10. The multiplexed digital PCR-based 'Droplex' shows a 91% concordance with next-generation sequencing (NGS), even with smaller sample sizes, and enables faster (within 1 day) and more convenient detection of NSCLC mutations compared to NGS. 😃 The Droplex test can detect 180 mutations in 11 key lung cancer-related genes, including RNA fusion variants (EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, HER2, NTRK1, NTRK2, and NTRK3). 👍 👍 Gencurix expects that the Droplex NSCLC Panel Test to address unmet diagnostic needs and target markets where current qPCR and NGS methods fall short. 👏 #Gencurix #digitalPCR #Droplex #NSCLC #Panel #DroplexNSCLCPanelTest #WCLC2024 #IASLC

🤝 Gencurix and Hitachi High-Tech (Japan) Collaborate to Develop Testing Services for Molecular Diagnosis of Cancer 👏 We’re excited to announce a new strategic partnership with Hitachi High-Tech Corporation, aiming to revolutionize molecular cancer diagnostics. By combining Gencurix's leading biomarker discovery technology with Hitachi High-Tech's expertise in in vitro diagnostics and digital innovation, we'll develop highly reliable and accurate testing services that advance personalized medicine.👍 This partnership will initially focus on the launch in Japan, with plans to expand these cutting-edge diagnostic services globally. Together, we are committed to improving cancer care by providing healthcare professionals with the tools they need to make accurate, timely and personalized treatment decisions.🔬 Stay tuned as we take steps to improve patient outcomes and quality of life around the world. 🌍 #Gencurix #HitachiHighTech #CancerDiagnostics #HealthcareInnovation #PersonalizedMedicine #GlobalHealth https://lnkd.in/eBrieSpd https://lnkd.in/g6AU76Bk